The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,384.00
Bid: 12,386.00
Ask: 12,390.00
Change: 52.00 (0.42%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,386.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-WHO says vaccine makers working non-stop to plug supply gap, urges patience

Thu, 28th Jan 2021 10:23

(Adds quote from WHO Europe vaccination expert)

* WHO urges solidarity amid vaccine rollout 'teething
problems'

* EU, Britain clash over delays in promised vaccine supply

* WHO's Kluge hopes 'extra future production' eases delays

* Russian vaccine data bound for Geneva -WHO Europe boss

By Stephanie Nebehay and John Miller

GENEVA, Jan 28 (Reuters) - The World Health Organization's
Europe director Hans Kluge said on Thursday vaccine
manufacturers were working non-stop to plug shortfalls in
supplies to countries struggling to contain the COVID-19
pandemic and urged them not to jostle for deliveries.

"Solidarity does not necessarily mean that each country in
the world starts (vaccinating) at exactly the same moment ...
The good understanding is that no one is safe before everyone is
safe," Kluge told an online news briefing.

Asked about delays in expediting Pfizer and
AstraZeneca vaccines to patients across the 27-nation
European Union, Kluge and a WHO-Europe vaccination expert,
Siddhartha Datta, appealed to governments and manufacturers to
cooperate in addressing "teething problems" in the rollout.

"The reality is there is a shortage of vaccines...(But) we
don't doubt that manufacturers and producers are working 24-7 to
bridge the gaps and we're confident the delays we are seeing now
are going to be made up by extra production in the future,"
Kluge said.

The WHO reiterated that vaccines should be shared equitably,
between poor and rich nations, to help end the pandemic with
Datta stressing COVID-19 vaccines were "a global public good".

As Kluge and Datta spoke, Europe's fight to secure COVID-19
vaccine supplies escalated as Britain demanded that it receive
all the shots it paid for after the EU asked AstraZeneca to
divert supplies from the UK.

The EU, whose members are far behind Israel, the United
Kingdom and the United States in dispensing vaccines, is
scrambling to obtain shots just as the West's biggest drugmakers
slow deliveries to the bloc due to production problems.

"We need to be patient, it will take time to vaccinate,"
Kluge said, adding that a total of 35 countries in Europe had
launched vaccinations with 25 million does administered so far.

PANDEMIC PARADOX

"This paradox, where communities sense an end is in sight
with the vaccine but, at the same time, are called to adhere to
restrictive measures in the face of a new threat, is causing
tension, angst, fatigue, and confusion. This is completely
understandable in these circumstances."

Kluge said continued high rates of transmission and emerging
variants of the virus made it urgent to vaccinate priority
groups, but acknowledged the rate of vaccine production and
distribution was not yet up to expectations.

He reiterated the WHO's stance that "vaccination passports"
- proof that somebody has been inoculated - will be important to
monitor inoculation coverage and efficacy of shots, but should
not be used as a litmus test for allowing people to travel.

Asked about WHO's scrutiny of Russia's Sputnik V vaccine,
Kluge said he had spoken with Moscow's ambassador on Wednesday
and that he could confirm that data needed by WHO scientists to
review the shot was en route to Geneva where the WHO is based.

The Russian vaccine is being distributed in Europe including
EU member state Hungary as well as elsewhere in the world, even
though the European Medicines Agency is not currently reviewing
it for approval.
(Reporting by Stephanie Nebehay and John Miller
Editing by Mark Heinrich)

More News
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.